A 68% Reduction in Recurrence Risk Sharpens the Growth Story
CG Oncology (NASDAQ: CGON) has delivered the kind of late-stage cancer result that can move a biotechnology company from promising science toward a more substantial commercial proposition. On November 16, the company…
